Список литературы

1. Goldring M.B. The musculoskeletal system. B. Articular cartilage. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, eds. Primer on the Rheumatic Diseases. Atlanta: Arthritis Foundation; 2001:10-16.

2. Poole A.R. Cartilage in health and disease. In: Koopman WJ, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology. Philadelphia: Lippincott, Williams & Wilkins; 2001:226–284.

3. Weinberger A., Simkin P.A. Plasma proteins synovial fluids of normal human joints. Semin Arthritis Rheum. 1989;19(1):66-76.

4. Kushner I., Somerville J.A. Permeability of human synovial membrane to plasma proteins. Arthritis Rheum 1971;14:560–570.

5. Levick J.R. A method for estimating macromolecular reflection by synovium, using measurements of intra-articular half lives. Ann Rheum Dis. 1998;57(6):339-44.

6. Simkin P.A. Fluid dynamics of the joint space and trafficking of matrix products. In: Seibel MJ, Robins SP, Bilezekian JP, eds. Dynamics of Bone and Cartilage Metabolism. New York: Academic Press; 1999:319-324.

7. McCarty D.J. Synovial fluid. In: Koopman WJ, ed. Arthritis and allied conditions: Textbook of rheumatology. Baltimore: Lippincott Williams & Wilkins 2001.

8. Swann D.A., Silver F.H., Slayter H.S., et al. The molecular structure and lubricating activity of lubricin isolated from bovine and human synovial fluids. Biochem J. 1985;225:195–201.

9. Simkin P.A., Bassett J.E., Koh E.M. Synovial perfusion in the human knee: A methodologic analysis. Semin Arthritis Rheum. 1995 25:56–66.

10. Levick J.R., McDonald J.N. Fluid movement across synovium in healthy joints: Role of synovial fluid macromolecules. Ann Rheum Dis. 1995;54:417–423.

11. Myers S.L., Brandt K.D. Effects of synovial fluid hyaluronan concentration and molecular size on clearance of protein from the canine knee. J Rheumatol. 1995;22:1732–1739.

12. Merry P., Williams R., Cox N., et al. Comparative study of intra-articular pressure dynamics in joints with acute traumatic and chronic inflammatory effusions: Potential implications for hypoxic-reperfusion injury. Ann Rheum Dis. 1991;50:917–920.

13. Gaffney K., Williams R.B., Jolliffe V.A., Blake D.R. Intra-articular pressure changes in rheumatoid and normal peripheral joints. Ann Rheum Dis. 1995;54:670-673.

14. Meyer K., Palmer J.W. The polysaccharide of the vitreous humor. J Biol Chem. 1934;107:629-634.

15. Weissman B., K. The structure of hyalobiuronic acid and hyaluronic acid from umbilical cord. J Am Chem Soc. 1954;76:1753-1757.

16. Weigel P.H., Hascall V.C., Tammi M. Hyaluronan synthases. J Biol Chem. 1997;272(22):3997-4000.

17. Toole B.P. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell Biol. 1990;2(5):839-44.

18. Goldring S.R., Goldring M.B. Biology of the normal joint. In: Harris Jr. ED, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, eds. Kelley’s Textbook of Rheumatology. 7 ed. Philadelphia: Elsevier Saunders; 2005:1-34.

19. Toole B.P. Hyaluronan in morphogenesis. J Intern Med. 1997;42:35-40.

20. Skelton T.P., Zeng C., Nocks A., Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol. 1998;140(2):431-46.

21. Knudson C.B. Hyaluronan receptor-directed assembly of chondrocyte pericellular matrix. J Cell Biol. 1993;120(3):825-34.

22. Hardingham T.E., Muir H. The specific interaction of hyaluronic acid with cartilage proteoglycans. Biochim Biophys Acta. 1972;279:401-405.

23. Buckwalter J.A., Rosenberg L.C. Electron microscopic studies of cartilage proteoglycans. Direct evidence for the variable length of the chondroitin sulfate-rich region proteoglycan subunit core protein. J Biol Chem. 1982;257(16):9830-9.

24. Hardingham T.E., Fosang A.J. Proteoglycans: many forms and functions. FASEB J. 1992;6:861-870.

25. Balazs E.A., Denlinger J.L. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. 1993;39:3-9.

26. Itano N., Sawai T., Yoshida M., et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999 274(35):25085-92.

27. Nishida Y., Knudson C.B., Nietfeld J.J., et al. Antisense inhibition of hyaluronan synthase-2 in human articular chondrocytes inhibits proteoglycan retention and matrix assembly. J Biol Chem. 1999;274(31):21893-9.

28. Di Cesare P.E., Abramson S.B. Pathogenesis of osteoarthritis. In: Harris Jr. ED, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, eds. Kelley’s Textbook of Rheumatology. 7 ed. Philadelphia: Elsevier Saunders; 2005:1493-1513.

29. Цветкова Е.С. Остеоартроз. В кн: Насонова В.А., Бунчук Н.В., ред. Ревматические болезни: Руководство для врачей. М: Медицина; 1997:385-396.

30. Smith MD., Triantafillou S., Parker A., et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24(2):365–371.

31. Petersson I.F. Occurrence of osteoarthritis the peripheral joints European populations. Ann Rheum Dis. 1996;55:659–661.

32. Felson D.T. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev. 1988;10:1–28.

33. Mankin H.J., Brandt K.D. Biochemistry and metabolism articular cartilage in osteoarthritis. In: Moskowitz RW, Howell DS, Goldberg VM, et al., eds. Osteoarthritis: Diagnosis and Medical/Surgical Management. Philadelphia: WB Saunders; 1992 109–54.

34. Muir H.Current and future trends in articular cartilage research and osteoarthritis. In: Kuettner KE, Schleyerbach R, Hascall VC, eds. Articular Cartilage and Biochemistry. New York: Raven Press; 1986:423–40.

35. Mankin H.J., Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. J Bone Joint Surg Am. 1970;52(3):424–34.

36. Mort J.S., Billington C.J. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res. 2001;3(6):337–41.

37. Sandy J.D., Lark M.W. Proteolytic degradation of normal and osteoarthritic cartilage matrix. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. Oxford: Oxford University Press; 1998:84.

38. Ryu J., Treadwell B.V., Mankin H.J. Biochemical and metabolic abnormalities in normal and osteoarthritic human articular cartilage. Arthritis Rheum. 1984;27(1):49–57.

39. Campbell I.K., Wojta J., Novak U., et al. Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor alpha and up-regulation by transforming growth factor-B basic fibroblast factor. Biochim Biophys Acta. 1994;1226(3):277–85.

40. Rath N.C., Oronsky A.L., Kerwar S.S. Synthesis of interleukin-1-like activity by normal chondrocytes in culture. Clin Imm Immunopathol. 1988;47(1):39–46.

41. Hedin P.J., Weitoft T., Hedin H., et al. Serum concentrations of hyaluronan and proteoglycan in joint disease: Lack association. J Rheumatol. 1991;18(10):1601–5.

42. Goldberg R.L., Huff J.P., Lenz M.E., et al. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34(7):799–807.

43. Manicourt D.H., Cornu O., Lenz M.E., et al. Rapid and sustained rise in the serum level of hyaluronan after anterior cruciate ligament transaction in the dog knee joint. J Rheumatol. 1995 22(2):262–9.

44. Sinigaglia L., Varenna M., Binelli L., et al. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 1995 54(2):144–7.

45. Sharif M., George E., Dieppe P.A. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. Arthritis Rheum. 1995;38(1):78–81.

46. Belcher C., Yaqub R., Fawthrop F., et al. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann Rheum Dis. 1997;56(5):299-307.

47. Tanimoto K., Ohno S., Fujimoto K., et al. Proinflammatory cytokines regulate the gene expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. Connect Tissue Res. 2001;42:187-195.

48. Smith M.M., Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987;7:113-122.

49. Bagga H., Burkhardt D., Sambrook P., March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33(5):946-50.

50. Salter D.M., Godolphin J.L., Gourlay M.S., et al. Analysis of human articular chondrocyte CD44 isoform expression and function in health and disease. J Pathol. 1996;179(4):396-402.

51. Chow G., Nietfeld J.J., Knudson C.B., Knudson W. Antisense inhibition of chondrocyte CD44 expression leading to cartilage chondrolysis. Arthritis Rheum. 1998;41(8):1411-9.

52. Knudson W., Loeser R.F. CD44 and integrin matrix receptors participate in cartilage homeostasis. Cell Mol Life Sci. 2002;59:36-44.

53. Pozo M.A., Balazs E.A., Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res. 1997;116:3-9.

54. Gomis A., Pawlak M., E.A., et al. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004;50(1):314-26.

55. Aihara S., Murakami N., Ishii R., et al. [Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis]. Nippon Yakurigaku Zasshi. 1992;100:359-365.

56. Gotoh S., Onaya J., Abe M., et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52:817-822.

57. Moore A.R., Willoughby D.A. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React. 1995;17:153-156.

58. Kawasaki K., Ochi M., Uchio Y., et al. Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen J Cell Physiol. 1999;179:142-148.

59. Ghosh P., Holbert C., Read R., Armstrong S. Hyaluronic acid (hyaluronan) in experimental osteoarthritis. J Rheumatol Suppl. 1995;43:155-7.

60. Creamer P., Sharif M., George E., et al. Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action. Osteoarthritis Cartilage. 1994;2(2):133-40.

61. Frean S.P., Abraham L.A., Lees P. In vitro stimulation of equine articular cartilage proteoglycan synthesis by hyaluronan and carprofen. Res Vet Sci. 1999;67:183-190.

62. Kikuchi T., Yamada H., Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage. 1996;4(2):99-110.

63. Kikuchi T., Sakuta T., Yamaguchi T. Effects of hyaluronan on cell proliferation and proteoglycan synthesis in rabbit ligamental cells. Int J Tissue React. 1996;18:87-95.

64. Fukuda K., Dan H., Takayama M., et al. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J Pharmacol Exp Ther. 1996;277:1672-1675.

65. Stove J., Gerlach C., Huch K., et al. Effects of hyaluronan on proteoglycan content of osteoarthritic chondrocytes in vitro. J Orthop Res. 2002;20(3):551-5.

66. Shimazu A., Jikko A., Iwamoto M., et al. Effects of hyaluronic acid on the release proteoglycan from the cell matrix in rabbit chondrocyte cultures in the presence and absence of cytokines. Arthritis Rheum. 1993;36:247-253.

67. Goto H., Onodera T., Hirano H., Shimamura T. Hyaluronic acid suppresses the reduction of collagen gene expression caused by interleukin-1 in cultured rabbit articular chondrocytes. Tohoku J Exp Med. 1999;187:1-13.

68. Homandberg G.A., Hui F., Wen C., et al. Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: I. In vitro. Osteoarthritis Cartilage. 1997;5:309-319.

69. Kang Y., Eger W., Koepp H., et al. Hyaluronan suppresses fibronectin fragment-mediated damage to human cartilage explant cultures by enhancing proteoglycan synthesis. J Orthop Res. 1999;17(6):858-69.

70. Comer J.S., Kincaid S.A., Baird A.N., et al. Immunolocalization of stromelysin, tumor necrosis factor (TNF) alpha, and TNF receptors in atrophied canine articular cartilage treated with hyaluronic acid and transforming growth factor beta. Am J Vet Res. 1996;57:1488-1496.

71. Takahashi K., Goomer R.S., Harwood F., et al. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta(IL-1beta), and tissue inhibitor of metalloproteinase -1 (TIMP-1) gene expression during the development osteoarthritis. Osteoarthritis Cartilage. 1999;7(2):182-90.

72. Yasui T., Akatsuka M., Tobetto K., et al. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase -1 (TIMP-1) in bovine articular chondrocytes. Biomed Res. 1992;13:343-348.

73. Nonaka T., Kikuchi H., Ikeda T., et al. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol. 2000;27(4):997-1004.

74. Tobetto K., Yasui T., Ando T., et al. Inhibitory effects of hyaluronan on [14C]arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol. 1992;60(2):79-84.

75. Yasui T., Akatsuka M., Tobetto K., et al. The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions. 1992;37(1-2):155-6.

76. Hirota W.Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto-prostaglandin F1alpha, prostaglandin F2alpha and interleukin-1beta in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg. 1998(36):35-38.

77. Punzi L., Schiavon F., Cavasin F., et al. The influence of intra-articular hyaluronic acid on PGE2 and cAMP fluid. Clin Exp Rheumatol. 1989;7:247-250.

78. Moseley R., Leaver M., Walker M., et al. Comparison of the antioxidant properties HYAFF®-11p75 AQUACEL® and hyaluronan towards reactive oxygen species in vitro. Biomaterials. 2002;23:2255-2264.

79. Sato H., Takahashi T., Ide H., et al. Antioxidant activity of synovial fluid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum. 1988;31(1):63-71.

80. Fukuda K., Takayama M., Ueno M., et al. Hyaluronic acid inhibits interleukin-1-induced superoxide anion in bovine chondrocytes. Inflamm Res. 1997;46:114-117.

81. Fukuda K., Oh M., Asada S., et al. Sodium hyaluronate inhibits interleukin -1-evoked reactive oxygen species of bovine articular chondrocytes. Osteoarthritis Cartilage. 2001;9:390-392.

82. Kvam B.J., Fragonas E., Degrassi A., et al. Oxygen-derived free radical(ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. Exp Cell Res. 1995;218:79-86.

83. Presti D., Scott J.E. Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH) radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct. 1994;12:281-288.

84. Takahashi K., Hashimoto S., Kubo T., et al. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J Orthop Res. 2001;19(3):500-3.

85. Takahashi K., Hashimoto S., Kubo T., et al. Effect of hyaluronan chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol. 2000;27(7):1713-20.

86. Tung J.T., Venta P.J., Caron J.P. Inducible nitric oxide expression in equine articular chondrocytes: effects of antiinflammatory compounds. Osteoarthritis Cartilage. 2002;10:5-12.

87. Rockey D.C., Chung J.J., McKee C.M., Noble P.W. Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments. Hepatology. 1998;27:86-92.

88. Peluso G.F., Perbellini A., Tajana G.F. The effect of high and low molecular weight hyaluronic acid on mitogen-induced lymphocyte proliferation. Curr Ther Res. 1990;47:437-443.

89. Forrester J.V., Balazs E.A. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology. 1980;40:435-446.

90. Pisko E.J., Turner R.A., Soderstrom L.P., et al. Inhibition of neutrophil phagocytosis and enzyme release by hyaluronic acid. Clin Exp Rheumatol. 1983;1:41-44.

91. Partsch G., Schwarzer C., Neumuller J., et al. Modulation of the migration and chemotaxis of PMN cells by hyaluronic acid. Z Rheumatol. 1989;48:123-128.

92. Forrester J.V., Lackie J.M. Effect of hyaluronic acid on neutrophil adhesion. J Cell Sci. 1981;50:329-344.

93. Tobetto K., Nakai K., Akatsuka M., et al. Inhibitory effects of hyaluronan on neutrophil-mediated cartilage degradation. Connect Tissue Res. 1993;29:181-190.

94. Fu L.L., Maffulli N., Chan K.M. Intra-articular hyaluronic acid following knee immobilisation for 6 weeks in rabbits. Clin Rheumatol. 2001;20:98-103.

95. Yoshioka M., Shimizu C., Harwood F.L., et al. The effects of hyaluronan during the development osteoarthritis. Osteoarthritis Cartilage. 1997;5(4):251-60.

96. Shimizu C., Yoshioka M., Coutts R.D., et al. Long-term effects of hyaluronan on experimental osteoarthritis in the rabbit knee. Osteoarthritis Cartilage. 1998;6(1):1-9.

97. Kobayashi K., Amiel M., Harwood F.L., et al. The long-term effects of hyaluronan during development of osteoarthritis following partial meniscectomy in a rabbit model. Osteoarthritis Cartilage. 2000;8(5):359-65.

98. Sonoda M., Harwood F.L., Wada Y., et al. The effects of hyaluronan on the meniscus and on the cartilage after partial meniscectomy. Am J Sports Med. 1997;25:755-762.

99. Marshall K.W., Manolopoulos V., Mancer K., et al. Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. J Orthop Res. 2000;18(3):416-25.

100. Yoshimi T., Kikuchi T., Obara T., et al. Effects of high-molecular-weight sodium hyaluronate on experimental osteoarthrosis induced by the resection of rabbit anterior cruciate ligament. Clin Orthop Relat Res. 1994(298):296-304.

101. Sakakibara Y., Miura T., Iwata H., et al. Effect of high-molecular-weight sodium hyaluronate on immobilized knee. Clin Orthop Relat Res. 1994(299):282-92.

102. Shimizu C., Kubo T., Hirasawa Y., et al. Histomorphometric and biochemical effect of various hyaluronans early osteoarthritis. J Rheumatol. 1998;25(9):1813-9.

103. Ghosh P., Read R., Armstrong S., et al. The effect of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Semin Arthritis Rheum. 1993;22(6 Suppl 1):18-30.

104. Ghosh P., Read R., Numata Y., et al. The effect of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism. Semin Arthritis Rheum. 1993;22(6 1):31-42.

105. Asari A., Miyauchi S., Matsuzaka S., et al. Molecular weight-dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol. 1998;61(2):125-35.

106. Ghosh P., Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32(1):10-37.

107. Frizziero L., Govoni E., Bacchini P. Intra-hyaluronic acid in the treatment osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol. 1998;16(4):441-9.

108. Listrat V., Ayral X., Patarnello F., et al. Arthroscopic of evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage. 1997;5(3):153-60.

109. Pasquali Ronchetti I., Guerra D., Taparelli F., et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology (Oxford). 2001;40(2):158-69.

110. Guidolin D.D., Ronchetti I.P., Lini E., et al. Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effects of 500-730 kDa sodium hyaluronate (Hyalgan) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthritis Cartilage. 2001;9(4):371-81.

111. Kikuchi T., Yamada H., Fujikawa K. Effects of high molecular weight hyaluronan on the distribution and movement of proteoglycan around chondrocytes cultured in alginate beads. Osteoarthritis Cartilage. 2001;9(4):351-6.

112. Larsen N.E., Lombard K.M., Parent E.G., Balazs E.A. Effect of hylan on cartilage and chondrocyte cultures J Orthop Res 1992;10(23-32).

113. Hulmes D.J., Marsden M.E., Strachan R.K., et al. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthritis Cartilage. 2004;12(3):232-8.

114. Morris E.A., Wilcon S., Treadwell B.V. Inhibition of interleukin 1-mediated proteoglycan degradation in bovine articular cartilage explants by addition of sodium hyaluronate. Am J Vet Res. 1992;53:1977-1982.

115. Abatangelo G., Botti P., Del Bue M., et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. I. Biochemical results. Clin Orthop Relat Res. 1989(241):278-85.

116. Jean Y.H., Wen Z.H., Chang Y.C., et al. Hyaluronic acid attenuates osteoarthritis development in the anterior cruciate ligament-transected knee: Association with excitatory amino acid release in the joint dialysate. J Orthop Res. 2006;24(5):1052-61.

117. Goto M., Hanyu T., Yoshio T., et al. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol. 2001;19:377-383.

118. Nonaka T., Kikuchi H., Shimada W., et al. Effects of hyaluronic acid on fibrinolytic factors in the synovial fluid (in vivo). Pathophysiology. 1999;6:41-44.

119. Tanaka M., Masuko-Hongo K., Kato T., et al. Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes. Rheumatol Int. 2006;26(3):185-90.

120. Maneiro E., de Andres M.C., Fernandez-Sueiro J.L., et al. The biological action of hyaluronan on human osteoartritic articular chondrocytes: the importance of molecular weight. Clin Exp Rheumatol. 2004;22(3):307-12.

121. Balazs E.A., Darzynkiewicz Z. The effect of hyaluronic acid on fibroblasts, mononuclear phagocytes and lymphocytes. Biology and Fibroblasts. 1973;66:237-252.

122. Balazs E.A.Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int. 2004;12:278-89.

123. Hakansson L., Hallgren R., Venge P. Regulation of granulocyte function by hyaluronic acid. In vitro and in vivo effects on phagocytosis, locomotion, and metabolism. J Clin Invest. 1980;66:298-305.

124. Amiel D., Toyoguchi T., Kobayashi K., et al. Long-term effect of sodium hyaluronate (Hyalgan) on osteoarthritis progression in a rabbit model. Osteoarthritis Cartilage. 2003;11(9):636-43.

125. Schiavinato A., Lini E., Guidolin D., et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. II. Morphological findings. Clin Orthop Relat Res. 1989(241):286-99.

126. Wenz W., Breusch S.J., Graf J., Stratmann U. Ultrastructural findings after intraarticular application of hyaluronan in a canine model of arthropathy. J Orthop Res. 2000;18:604-612.

127. Cefalu C.A., Waddell D.S. Viscosupplementation: treatment alternative for osteoarthritis of the knee. Geriatrics. 1999;54(10):51-4, 57.

128. Moreland L.W. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5(2):54-67.

129. Jordan K.M., Sawyer S., Coakley P., et al. The use of conventional and complementary treatments for knee osteoarthritis in the community. Rheumatology (Oxford). 2004;43:381-384.

130. Arrich J., Piribauer F., Mad P., et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ. 2005;172(8):1039-43.

131. Modawal A., Ferrer M., Choi H.K., Castle J.A. Hyaluronic acid injections relieve knee pain. J Fam Pract. 2005;54(9):758-67.

132. Bellamy N., Campbell J., Robinson V., et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006(2):CD005321.

133. Lo G.H., LaValley M., McAlindon T., Felson D.T. Intra-articular hyaluronic acid in treatment of the knee osteoarthritis: a meta- analysis. JAMA. 2003;290(23):3115-21.

134. Wang C.T., Lin J., Chang C.J., et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86-A(3):538-45.

135. Altman R., Brandt K., Hochberg M., et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996;4(4):217-43.

136. Altman R., Alarcon G., Appelrouth D., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34(5):505-14.

137. Altman R.D.Classification of disease: osteoarthritis. Semin Arthritis Rheum. 1991;20(6 Suppl 2):40-7.

138. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.

139. Hammesfahr J.F., Knopf A.B., Stitik T. Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Orthop. 2003;32(6):277-83.

140. Hamburger M.I., Lakhanpal S., Mooar P.A., Oster D. Intra- articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003;32(5):296-309.

141. Raynauld J.P., Goldsmith C.H., Bellamy N., et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2005;13(2):111-9.

142. Arensi F.Comparison efficacy and therapeutic safety of two treatments based on hyaluronic acid (Go-On and Hyalgan) in knee osteoarthritis. Minerva Ortop Traumatol. 2006;57:105-11.

143. Kotevoglu N., Iyibozkurt P.C., Hiz O., et al. A prospective randomised controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int. 2006;26(4):325-30.

144. Kirchner M., Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-62.

145. Lee P.B., Kim Y.C., Lim Y.J., et al. Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial. J Int Med Res. 2006;34(1):77-87.

146. Karatosun V., Unver B., Gocen Z., Sen A. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee. A prospective, randomized, double-blind study with long term follow-up. Clin Exp Rheumatol. 2005;23(2):213-8.

147. Gur A., Bahadir P., Sarac A.J., et al. A prospective randomised placebo controlled clinical trial comparing the tolerability and efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Ann Rheum Dis. 2006;65(Suppl II):230.

148. Raman R., Dutta A., Day N., et al. Aprospective randomised controlled clinical trial comparing the efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee. Ann Rheum Dis. 2006;65(Suppl II):403.

149. Беленький А.Г., Денисов Л.Н., Панасюк Е.Ю., и соавт. Препарат гиалуроновой кислоты "Остенил"® для лечения гонартроза. Результаты многоцентрового рандомизированного, маскированного годичного исследования. Научно-практическая ревматология. 2005, №6:49-52.

150. Гроппа Л.Г., Мошняга М., Руссу А. Эффективность препарата Synvisc у больных остеоартрозом. Научно-практическая ревматология. 2001, №3:30.

151. Зайцева Е.М., Алексеева Л.И. Оценка эффективности и переносимости препарата “Синвиск” у больных с остеоартрозом коленных суставов. Научно-практическая ревматология. 2003, Приложение к №2:39.

152. Petrella R.J. Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil. 2005;84(4):278-83; quiz 284, 293.

153. Petrella R.J., Petrella M. Long-term persistence with intra-articular hyaluronic acid treatment of the knee: Differences with other treatments in clinical outcomes and associated costs. Ann Rheum Dis. 2005;64(Suppl III):401.

154. Waddell D.D., Bricker D.C. Hylan G-F 20 reduces the probability of progression to total knee replacement in knee osteoarthritis. Ann Rheum Dis. 2003;62(Suppl I):FRI0243.

155. Leopold S.S., Warme W.J., Pettis P.D., Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc) in patients receiving more than one course treatment. J Bone Joint Surg Am. 2002;84-A(9):1619-23.

156. Pagnano M., Westrich G.Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthritis Cartilage. 2005;13(9):751-61.

157. Puttick M.P., Wade J.P., Chalmers A., et al. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995;22(7):1311-4.

158. Theiler R., Bruhlmann P. Overall tolerability and analgesic activity of intra-articular sodium hyaluronate in the treatment of the knee osteoarthritis. Curr Med Res Opin. 2005;21(11):1727-33.

159. Kemper F., Gebhardt U., Meng T., Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-9.

160. Magilavy D., Polisson R., Murray C. Acute local reaction to intra-articular Hylan G-F 20 (Synvisc): part I. J Bone Joint Surg Am. 2003; 85-A(8):1618-9; author reply 1619-20.

161. D.B., McPherson J.M., Polisson R. Pseudoseptic reactions to Hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res. 2004(429):349-50; author reply 350-1.

162. Roos J., Epaulard O., Juvin R., et al. Acute pseudoseptic arthritis after intraarticular sodium hyaluronan. Joint Bone Spine. 2004;71(4):352-4.

163. Maheu E., Bonvarlet J. Acute pseudo-septic arthritis post hyaluronane (HA) intra-articular (IA) injections. Results of a french survey in rheumatology practice. Ann Rheum Dis. 2003;62(Suppl I):FRI0240.

164. Conrozier T., Vignon E. Is there evidence to support the inclusion of viscosupplementation in the treatment paradigm for patients with hip osteoarthritis? Clin Exp Rheumatol. 2005;23(5):711-6.

165. Fernandez Lopez J.C., Ruano-Ravina A. Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2006;14(12):1306-11.

166. Tikiz C., Unlu Z., Sener A., et al. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol. 2005;24(3):244-50.

167. Qvistgaard E., Christensen R., Torp-Pedersen S., Bliddal H. Intra-articular treatment of hip osteoarthritis: randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartilage. 2006;14(2):163-70.

168. Migliore A., Massafra U., Capuano A., et al. Study to compare Hyalubrix® and intra-articular local anaesthetic in the treatment of symptomatic hip osteoarthritis. Ann Rheum Dis. 2006;65(Suppl II):399.

169. Dore D.D.Treatment of hip osteoarthritis pain with intraarticular hyalgan injections. Arthritis Rheum. 2004;52(Suppl):AB1146.

170. A., Tormenta S., U., et al. Ultrasound guided intra-articular administration of hylan G-F 20 (Synvisc®) in 223 patients suffering from symptomatic hip osteoarthritis. Ann Rheum Dis. 2005;64(SupplIII):487.

171. БеленькийА.Г.Гиалуронат (Остенил) в лечении коксартроза. Научно-практическая ревматология. 2006, №2:76.

172. Пак Ю.В., Меньшикова И.В., Сергиенко С.А., Петухова Н.В. Применение препаратов гиалуроновой кислоты при коксартрозе. Научно-практическая ревматология. 2005(№3):95.

173. БеленькийА.Г. Патология околосуставных мягких тканей плечевого сустава — диагностика и лечение М.: РМАПО; 2005б - 62с.

174. Meislin R.J., Sperling J.W., Stitik T.P. Persistent shoulder pain: epidemiology, pathophysiology, and diagnosis. Am J Orthop. 2005;34(12 Suppl):5-9.

175. Leardini G., Perbellini A., Franceschini M., Mattara L. Intra-articular injections of hyaluronic acid in the treatment of painful shoulder. Clin Ther. 1988;10(5):521-6.

176. Itokazu M., Matsunaga T.Clinical evaluation of high-molecular-weight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. Clin Ther. 1995;17(5):946-55.

177. Rovetta G., Monteforte P. Intraarticular injection of sodium hyaluronate plus steroid versus steroid in adhesive capsulitis of the shoulder. Int J Tissue React. 1998;20(4):125-30.

178. Petrella R.J.Hyaluronic acid in treatment of osteoarthritis of the shoulder. Ann Rheum Dis. 2005;64(Suppl III):481

179. Calis M., Demir H., Ulker S., et al. Is intraarticular sodium hyaluronate injection an alternative treatment in patients with adhesive capsulitis? Rheumatol Int. 2006;26(6):536-40.

180. Altman R., Moskowitz R., Jacobs S., et al. A double-blind, randomized trial of intra-articular injection of sodium hyaluronate (Hyalgan®) for the treatment of chronic shoulder pain. Arthritis Rheum. 2005;52(Suppl):S461.

181. Altman R., R., DeCastro G. Effectiveness of intra-articular hyaluronan therapy in osteoarthritic shoulder patients refractory to non-surgical treatmen. Arthritis Rheum. 2006;53(3):AB1695.

182. Bertolami C.N., Gay T., Clark G.T., et al. Use of sodium hyaluronate in treating temporomandibular joint disorders: a randomized, double-blind, placebo-controlled clinical trial. J Oral Maxillofac Surg. 1993;51(3):232-42.

183. Guarda-Nardini L., Masiero S., Marioni G. Conservative treatment of temporomandibular joint osteoarthrosis: intra-articular injection of sodium hyaluronate. J Oral Rehabil. 2005;32(10):729-34.

184. Salk R., Chang T., D’Costa W., et al. Viscosupplementation (hyaluronans) in the treatment of ankle osteoarthritis. Clin Podiatr Med Surg. 2005;22(4):585-97, vii.

185. Salk R.S., Chang T.J., D’Costa W.F., et al. Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study. J Bone Joint Surg Am. 2006;88(2):295-302.

186. Stahl S., Karsh-Zafrir I., Ratzon N., Rosenberg N. Comparison of intraarticular injection of depot corticosteroid and hyaluronic acid for treatment of degenerative trapeziometacarpal joints. J Clin Rheumatol. 2005;11(6):299-302.

187. Fuchs S., Monikes R., Wohlmeiner A., Heyse T. Intra-articular hyaluronic acid compared with corticoid injections for the treatment of rhizarthrosis. Osteoarthritis Cartilage. 2006;14(1):82-8.

188. Cabezas R., Rodriguez de la Serna A., Riviere M. Local treatment of rhizarthrosis (Suplasyn) versus dexamethasone, a prospective randomized study. Ann Rheum Dis. 2003;62(Suppl II):SAT0027.

189. Petrella R.J.Peri-articular hyaluronic acid for acute ankle sprain. Ann Rheum Dis. 2005;64(III):385.

190. Komatsubara Y., Sohen S., Inoue K., et al. A multi-center randomized comparative phase IV clinical dose-response study of high molecular weight hyaluronic acid (Suvenyl) on knee pain in rheumatoid arthritis. Ann Rheum Dis 2005;64(Suppl III):415.

191. Komatsubara Y., Sohen S., Inoue K., et al. Long-term study of the effect of high molecular weight hyaluronic acid (Suvenyl) on knee pain in rheumatoid arthritis. Ann Rheum Dis. 2005;64(Suppl III):416.

192. Doherty M., Dougados M. Evidence-based management of osteoarthritis: practical issues relating to the data. Best Pract Res Clin Rheumatol. 2001;15(4):517-25.

193. Creamer P.Osteoarthritis pain and its treatment. Curr Opin Rheumatol. 2000;12(5):450-5.

194. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905-15.

195. Simon L.S., Lipman A.G., Jacox A.K., et al. Pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. 2nd ed, Glenview (IL): American Pain Society (APS); 2002 (Clinical practice guideline; no.2).

196. Jordan K.M., Arden N.K., Doherty M., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55.

197. Zhang W., Doherty M., Arden N., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669-81.

198. American Academy of Orthopaedic Surgeons. AAOS clinical guideline on osteoarthritis of the knee. Rosemont (IL): American Academy of Orthopaedic Surgeons; 2003.

199. Institute for Clinical Systems Improvement (ICSI). Diagnosis and treatment of adult degenerative joint disease (DJD) of the knee. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2004.